Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4244320 | 0.84 | CYP3A4 (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4245414 | 0.83 | CYP3A4 (0.45) | CYP3A4TDP1RAB9A | |
| SCHEMBL893483 | 0.81 | TDP1 (0.50) | CYP3A4TDP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL893511 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL893633 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4959397 | 0.79 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL4959571 | 0.79 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL4390521 | 0.79 | CYP3A4 (0.56) | CYP3A4 | |
| SCHEMBL9943656 | 0.78 | CYP3A4 (0.67) | CYP3A4 | |
| SCHEMBL4245411 | 0.78 | CYP3A4 (0.46) | CYP3A4TDP1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081917-A2 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | Abbott Laboratories (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008027932-A2 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | disclosed |